RIGHT Fund Technical Accelerator Award

RF-TAA-2020-001

The RIGHT investments for real impact

The Technical Accelerator Award (TAA) is a new addition to the RIGHT Fund 2020 Request for Proposals. The purpose of this award is to develop proof-of-concept or additional scientific results that can be used to support a future Product Development Award application. Projects should reflect investment focus and disease priorities of the RIGHT Fund.

1. RIGHT Fund background

Infectious diseases remain a leading cause of death worldwide, disproportionately affecting low income countries and especially young children. The RIGHT Fund was established as a public private partnership between the Korean government, pharmaceutical companies, and the Bill & Melinda Gates Foundation (BMGF) with the goal of delivering transformative and innovative technologies for therapeutics, vaccines, and diagnostics which can ameliorate the burden of infectious disease. We seek to leverage Korea’s innovation and industry successes in vaccine development, manufacturing, and technology to promote global health equity by advancing the discovery and development of new affordable and applicable products to meet the public health needs of the world’s poorest populations.

The RIGHT Fund seeks original and innovative concepts for vaccines, therapeutics, and diagnostics to alleviate the acquisition, progression, or transmission of infectious diseases emerging and endemic in developing countries. Towards this vision and through this 2019 RFP, the RIGHT Fund aims to support up to ten research projects that involve collaborations between Korean and international research organizations/companies.

Collaborations between investigators are a preferred component of the proposals and applicants should outline a concrete framework for the collaboration between partners. The grant will be managed by the RIGHT Fund with payment contingencies well-coordinated to ensure that key milestones are met, and that the collaborative nature of each grant is maintained.
2. Investment eligibility

Mandatory requirement
RIGHT Fund investments will be awarded to existing or new partnerships that includes at least one Korean entity with a capacity of health intervention R&D and the expertise to identify projects that represent substantial additions to the field.

RIGHT Fund focuses on diseases for which there is a Korean company/academic or government research institution with the capability and the development platform to advance/improve existing products and delivery capabilities.

Eligible partnerships

<table>
<thead>
<tr>
<th>Korean entity</th>
<th>Non-Korean entity</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Korean corporations (or entities with a research facility in Korea)</td>
<td>• Life Science/Healthcare companies</td>
</tr>
<tr>
<td>• Not-for-profit research organizations and foundations</td>
<td>• Not-for-profit research organizations and foundations</td>
</tr>
<tr>
<td>• Government research institutions</td>
<td>• Product Development Partnerships</td>
</tr>
<tr>
<td>• Academic institutions</td>
<td>• Government research institutions</td>
</tr>
<tr>
<td></td>
<td>• Academic institutions</td>
</tr>
</tbody>
</table>

Eligibility criteria: You will not be eligible for the multiple TAAs for the same technology development or target product. The RIGHT Fund reserves the right to determine eligibility of applicants and public health priority among proposals at its discretion.

Review process: In order to more rapidly deliver results and increase the impact of the award, a shorter review & decision (4-6 months) process for TAA proposals will be implemented. No interview required.

Acceptance of Global Access Policy: All existing and future partners within the partnership will also be required to sign Global Access Agreements to provide access to relevant data, intellectual property, and product use. RIGHT Fund’s access policies can be viewed at http://rightfund.org/investments/access-policy/
3. Funding opportunity

**Target diseases:** Infectious diseases endemic and emerging in developing countries.

**Technology Interventions:** Diagnostics, Therapeutics & Vaccines

**Award amount:** Up to 500,000,000 Korean won (KRW) per project

**Project duration:** The duration of the funding is up to one (1) year.

**Focus areas and Development stages:**

- Find RIGHT Fund’s investment area at [www.rightfund.org/investments/investment-area/](http://www.rightfund.org/investments/investment-area/)
- The TAA supports the initiation of “exploratory” projects to prove new concepts or approaches by producing preliminary supporting data
- The scope of work should target a **single go/no go decision point** towards a sustainable development plan eligible for a subsequent Product Development Award application.

The scope of research includes, but is **not limited to:**

**Diagnostics:** Laboratory verification of new or improved technologies for better usage in low resourced setting; identification of pathogen or host biomarkers of the disease; small scale validation of ICT integrated platforms for disease surveillance.

**Therapeutics:** Proof of concept of repurposing existing drugs (new regimen, fixed combination) in animal model or a pilot trial in human; validation of new drug candidates for safety and efficacy in animal models.

**Vaccines:** Validation of new vaccine candidates for safety, immunogenicity & efficacy in animal models; a pilot dose escalation study in human for new vaccine candidate; proof of concept of new vaccine targets, host or pathogen biomarkers of disease, adjuvants in animal model; proof of concept of new DNA/RNA vaccine delivery technologies; feasibility studies (process qualification & optimization) prior to scale-up for clinical trials.

**Exclusions:**

1) Personnel or indirect costs are not supported.
2) Requests for capital investments.
3) Duplicate expense claims with other funding sources.

[End of Document]